For the quarter ending 2025-09-30, APLT had -$18,476K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -18,990 | -43,155 |
| Stock-based compensation expense | 1,142 | 3,587 |
| Amortization of insurance premium | 0 | 0 |
| Amortization of operating lease right-of-use assets | 111 | 213 |
| Amortization of leasehold improvements | 0 | 1 |
| Change in operating lease liability | -102 | -193 |
| Change in fair value of warrant liabilities | 2,369 | -4,541 |
| Prepaid expenses | 15,619 | -158 |
| Accounts payable | -135 | 428 |
| Accrued expenses and other current liabilities | 12,823 | -5,475 |
| Other liabilities | 0 | 0 |
| Net cash used in operating activities | -18,401 | -48,977 |
| Net cash provided by investing activities | 0 | 0 |
| Proceeds from issuance of common stock, net of issuance costs | -1 | - |
| Employee stock purchase plan common stock issuance | 20 | - |
| Restricted stock units released settlement of payroll taxes | 94 | - |
| Repayments of short-term borrowings | 0 | 0 |
| Exercise of common warrants | 0 | 0 |
| Exercise of stock options | 0 | 0 |
| Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs | - | 0 |
| Net cash (used) provided by financing activities | -75 | 0 |
| Net (decrease) increase in cash and cash equivalents | -18,476 | -48,977 |
| Cash and cash equivalents at beginning of period | 79,398 | - |
| Cash and cash equivalents at end of period | 11,945 | - |
Applied Therapeutics, Inc. (APLT)
Applied Therapeutics, Inc. (APLT)